Clinical Trial Update: Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer) [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 trial of cyclosporin A for triple-negative breast cancer with DNA damage repair deficiency has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Cyclosporin A (cyclosporine)

Snippet

Sponsor: Virginia G. Kaklamani | Conditions: Triple Negative Breast Cancer, DNA Damage Repair Deficiency | EARLY_Phase 1 | Status: WITHDRAWN